Figure S7 from Immunoproteasome Activation Expands the MHC Class I Immunopeptidome, Unmasks Neoantigens, and Enhances T-cell Anti-Myeloma Activity
Year: 2026
Type: other
Abstract: Figure S7. Effect of Compound A pretreatment in vitro on the growth of E.G7-Ova-GFP-Luc tumors in vivo. a. Schematic representation of the experimental details with a timeline of treatments and tumor measurements. b. Phase contrast and FITC images of E.G7-Ova and E.G7-Ova-GFP-Luc cells. Scale bar = 100µm c. Relative luciferase activity in E.G7-Ova and E.G7-Ova-GFP-Luc cells. d. TBW for individual mice treated with either vehicle or Compound A. e. Average total flux as a measure of tumor burden in mice injected with vehicle or Compound A pretreated E.G7-Ova-Luc-GFP cells. Tumor burden (y-axis) was quantified as total flux (p/s) and monitored post-implantation (x-axis). Total flux represents a measure of the radiance (photons/sec) in each pixel integrated over the ROI area (cm2) x 4π. Average radiance was calculated by summing the radiance from each pixel within the ROI and then dividing by the number of pixels, resulting in units of photons/second/cm²/steradian. f. BLI of E.G7-Ova-GFP-Luc tumors from vehicle and Compound A-treated cells. Negative control represents an OT-1 mouse that was not injected with E.G7-Ova-GFP-Luc cells nor treated. Scale bar = 2 cm g. Percent survival of mice following injection of E.G7-Ova-GFP-Luc cells pretreated with either vehicle or Compound A.
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: gold
OpenAlex ID: W7164994861